Venture forces invest millions in new type of treatment for particularly aggressive form of cancer

Dr Ben Davis is an NMR spectroscopist and biophysicist by training, although since 2022 he has focussed on Business Development. However, he still maintains an active interest in developing new methods to enable Fragment Based Drug Discovery, particularly against challenging targets. Ben studied for his PhD in protein folding with Professor Alan Fersht at Cambridge University, and then studied molecular interactions at UCL before joining RiboTargets, now Vernalis, in 1998. He has contributed to seven books on FBDD since 2012, and has been an author on more than thirty scientific publications. He is a frequent speaker at scientific conferences.

Kerry brings nearly 30 years of drug discovery experience across government, pharmaceutical (MSD and GlaxoSmithKline) and contract research industries (Transpharmation Ltd, Sygnature Discovery Ltd), including 8 years in business development. During this time, Kerry has successfully driven sales growth globally across standalone services and fully integrated drug discovery programmes amounting to £millions per year and fostered key strategic partnerships with biotechs and VCs. Kerry completed her Master’s in Business Administration with the Open University in 2021.